Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Reviewthreo Ifenprodil hemitartrate is a potent σ receptor agonist (Ki values are 59.1 and 2 nM for σ1 and σ2 receptors respectively) and GluN2B (formally NR2B) subunit-selective NMDA receptor antagonist (IC50 values are 0.22 and 324.8 μM at GluN2B and GluN2A respectively). Displays ~8-fold reduced affinity at α-adrenoceptors compared to Ifenprodil (Cat.No. 0545). Inhibits the hERG potassium channel (IC50 = 88 nM) and exhibits antiarrhythmic activity in vivo.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
M. Wt | 400.49 |
Formula | C21H27NO2.½C4H6O6 |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
PubChem ID | 11957579 |
InChI Key | DMPRDSPPYMZQBT-UHFFFAOYSA-N |
Smiles | OC(C=C3)=CC=C3[C@H](O)[C@H](C)N2CCC(CC2)CC1=CC=CC=C1.OC(C=C6)=CC=C6[C@H](O)[C@H](C)N5CCC(CC5)CC4=CC=CC=C4.OC(C=C9)=CC=C9[C@@H](O)[C@@H](C)N8CCC(CC8)CC7=CC=CC=C7.OC(C=C%12)=CC=C%12[C@@H](O)[C@@H](C)N%11CCC(CC%11)CC%10=CC=CC=C%10.O=C(O)C(O)C(O)C(O)=O.O=C(O)C(O)C(O)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Hashimoto and London (1995) Interactions of erythro-ifenprodil, threo-ifenprodil and erythro-iodoifenprodil, and eliprodil with subtypes of σ receptors. Eur.J.Pharmacol. 273 307 PMID: 7737340
Avenet et al (1996) Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur.J.Pharmacol. 296 209 PMID: 8838458
Monassier et al (2007) σ2-receptor ligand-mediated inhibition of inwardly rectifying K+channels in the heart. J.Pharmacol.Exp.Ther. 322 341 PMID: 17460149
Keywords: threo Ifenprodil hemitartrate, threo Ifenprodil hemitartrate supplier, NR2B, selective, NMDA, antagonists, receptors, s, σ, sigma, agonist, ionotropic, glutamate, iGluR, GluN2B, Sigma-Related, Receptors, 2892, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for threo Ifenprodil hemitartrate include:
Lassus et al (2018) Glutamatergic and dopaminergic modulation of cortico-striatal circuits probed by dynamic calcium imaging of networks reconstructed in microfluidic chips. Sci Rep 8 17461 PMID: 30498197
Gasperini et al (2015) Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. Sci Rep 22 772 PMID: 25490055
There are currently no reviews for this product. Be the first to review threo Ifenprodil hemitartrate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.